$8m · Other round · Healthtech · London, UK
London-based orthopaedic implant company OSSTEC has closed $8m in funding led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, OTIF Ventures and Empirical Ventures. The round will fund US regulatory clearance and first-in-human procedures for its ASCENT Cementless Partial Knee system, according to the OTIF investor announcement.
Biological fixation targets a gap in partial knees
OSSTEC is an Imperial College London spinout developing 3D-printed implants with a porous structure intended to encourage bone to grow into the implant. ASCENT applies that fixation platform to partial knee replacement, paired with CLARITY instruments for the surgical procedure.
Partial replacement preserves more of a patient's natural knee than a total replacement and can support faster recovery, but it remains used in a minority of eligible cases. OSSTEC argues that cementless fixation can remove operating-room steps and reduce loosening risk by creating a biological bond between bone and implant.
The commercial opportunity depends on more than the implant design. Surgeons need reliable instrumentation, training and clinical evidence, while hospitals need predictable procedures and a supply chain that supports case scheduling. Funding both the device and the surgeon-support system is therefore essential to adoption; a technically successful implant can still struggle if the surrounding workflow is difficult to learn.
FDA clearance is the next value-setting milestone
The capital will take ASCENT and CLARITY through FDA clearance toward first US procedures planned for the first half of 2027. OSSTEC also intends to train surgeon faculty at specialist partial-knee centres and advance other products built on the same fixation platform.
That sequence gives investors a clear development path: regulatory review, first procedures, clinical follow-up and then broader commercial rollout. The main execution risk is whether early surgical results support the claimed benefits while the company builds manufacturing and support capacity. If the platform performs consistently, OSSTEC could reuse its fixation technology across additional implants rather than commercialising each product from a blank starting point.
Sources checked:
OTIF investor announcement · OSSTEC company website · Tech.eu Funding Explorer
